Extended Data Table 1 Combined deletion and mutational data for tumours listed in Fig. 1

From: PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies

  1. Mutations and resulting amino-acid changes in NF1, SUZ12 and EED are shown. H3K27me3 staining results, when performed, are indicated and tumours are classified as strongly positive, negative (loss) or partial loss (ploss). The majority of MPNSTs harbour defects in the p53 pathway.
Back to article page